XOMA Corporation Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Aronora (Details)

Royalty and Commercial Payment Purchase Agreements - Aronora (Details)		1 Months Ended	3 Months Ended		6 Months Ended
	Apr. 07, 2019 USD ($) item multiplier	Sep. 30, 2019 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Agreements
Payments of consideration under RPAs, AAAs and CPPAs					$ 37,000,000	$ 14,650,000
Contingent consideration under RPAs, AAAs and CPPAs			$ 3,000,000		3,000,000		$ 7,000,000
Short-term royalty and commercial payment receivables			14,257,000		14,257,000		14,215,000
Royalty purchase agreement asset impairment			9,000,000	$ 1,575,000	9,000,000	$ 1,575,000
Aronora
Agreements
Decrease in long-term royalty and commercial rights receivables due to impairment					$ 9,000,000
Aronora \| Royalty Purchase Agreement
Agreements
Number of drug candidates \| item	5
Non-royalties to be received (as a percent)	10.00%
Future non-royalty payments to be received (as a percent)	5.00%
Multiplier for cumulative amount of consideration paid \| multiplier	2
Payments of consideration under RPAs, AAAs and CPPAs	$ 6,000,000.0	$ 3,000,000.0
Threshold amount of cumulative royalties on net sales per product	250,000,000.0
Maximum royalty milestone payments to be paid per product	85,000,000.0
Acquisition of royalty and commercial payment receivables, Long-Term	9,000,000.0
Contingent consideration under RPAs, AAAs and CPPAs	3,000,000.0
Royalty purchase agreement asset impairment			9,000,000.0
Amount of increase in allowance for credit loss			9,000,000.0
Amount of allowance for credit losses							$ 0
Decrease in long-term royalty and commercial rights receivables due to impairment			$ 9,000,000.0
Aronora \| Royalty Purchase Agreement \| Minimum
Agreements
Threshold amount of cumulative royalties on net sales per product	25,000,000.0
Aronora \| Royalty Purchase Agreement \| SVB Loan
Agreements
Payments of consideration under RPAs, AAAs and CPPAs	$ 3,000,000.0
Aronora \| Royalty Purchase Agreement \| Bayer Products
Agreements
Number of drug candidates \| item	3
Number of drug candidates subject to exclusive license option \| item	1
Royalties entity has right to receive (as a percent)	100.00%
Non-royalties to be received (as a percent)	10.00%
Contingent future cash payment for each product	$ 1,000,000.0
Aronora \| Royalty Purchase Agreement \| Bayer Products \| Maximum
Agreements
Contingent consideration under RPAs, AAAs and CPPAs	$ 3,000,000.0
Aronora \| Royalty Purchase Agreement \| Non-Bayer Products
Agreements
Number of drug candidates	2
Non-royalties to be received (as a percent)	10.00%